Cytosorbents (CTSO) Form 4: Deliargyris Receives RSUs and $1 Options
Rhea-AI Filing Summary
Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corporation (CTSO), was granted equity awards on 08/08/2025. The filing reports an award of 70,000 restricted stock units (RSUs) that vest in equal parts on the first and second anniversaries of the grant, and a grant of 95,000 stock options with an exercise price of $1 that vest one-half on the first anniversary, one-fourth on the second and one-fourth on the third anniversary of the grant.
The disclosure shows these RSUs will settle into common stock upon vesting and notes certain RSUs that vest on a Change In Control (120,000 and 55,000 RSUs). Following the reported transactions, the reporting person beneficially owns 473,025 shares (direct). All information is taken from the Form 4 filing text.
Positive
- None.
Negative
- None.
Insights
TL;DR: Officer received routine compensation awards: 70,000 RSUs and 95,000 options at $1; total beneficial ownership now 473,025 shares.
The Form 4 documents compensation-related equity grants to the Chief Medical Officer on 08/08/2025: 70,000 RSUs vesting over two years and 95,000 options with a $1 exercise price and a three-step vesting schedule. The filing also itemizes previously granted RSUs that may vest on a change in control and discloses 197,525 currently owned shares as part of the 473,025 total. The filing is a standard insider compensation disclosure; the document does not provide outstanding share count or market context to assess dilution.
TL;DR: Grants follow plan terms with service-based vesting and change-in-control provisions; disclosure is consistent with routine executive compensation reporting.
The Form 4 explicitly describes service-vested RSUs and time-based stock options granted under the company's long-term incentive plan, including specific vesting schedules and change-in-control settlement language for certain prior RSUs. These are compensation mechanics disclosed as required; the filing does not include information on total dilution, grant rationale, or performance conditions beyond the stated vesting terms.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 95,000 | $0.00 | -- |
| Grant/Award | Common Stock | 70,000 | $0.00 | -- |
Footnotes (1)
- These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Includes: (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022; (continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and of which 30,500 remain unvested as of the date hereof; and (continued from footnote 3) (iv) 197,525 shares of Common Stock owned by the reporting person. These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
